Rajan KB, Weuve J, Barnes LL, Wilson RS, Evans DA. Prevalence and incidence of clinically diagnosed Alzheimer’s disease dementia from 1994 to 2012 in a population study. Alzheimers Dement. 2019;15(1):1–7.
Article
PubMed
Google Scholar
Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353–6.
Article
CAS
PubMed
Google Scholar
Ashton NJ, Hye A, Rajkumar AP, Leuzy A, Snowden S, Suarez-Calvet M, et al. An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders. Nat Rev Neurol. 2020;16(5):265–84.
Article
PubMed
Google Scholar
Blennow K. A review of fluid biomarkers for Alzheimer’s disease: moving from CSF to blood. Neurol Ther. 2017;6(Suppl 1):15–24.
Article
PubMed
PubMed Central
Google Scholar
Zetterberg H. Blood-based biomarkers for Alzheimer’s disease-an update. J Neurosci Methods. 2019;319:2–6.
Article
CAS
PubMed
Google Scholar
Zetterberg H, Burnham SC. Blood-based molecular biomarkers for Alzheimer’s disease. Mol Brain. 2019;12(1):26.
Article
PubMed
PubMed Central
CAS
Google Scholar
O’Bryant SE, Mielke MM, Rissman RA, Lista S, Vanderstichele H, Zetterberg H, et al. Blood-based biomarkers in Alzheimer disease: current state of the science and a novel collaborative paradigm for advancing from discovery to clinic. Alzheimers Dement. 2017;13(1):45–58.
Article
PubMed
Google Scholar
Figurski MJ, Waligorska T, Toledo J, Vanderstichele H, Korecka M, Lee VM, et al. Improved protocol for measurement of plasma beta-amyloid in longitudinal evaluation of Alzheimer’s Disease Neuroimaging Initiative study patients. Alzheimers Dement. 2012;8(4):250–60.
Article
CAS
PubMed
PubMed Central
Google Scholar
Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer’s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19(5):422–33.
Article
CAS
PubMed
Google Scholar
Manzine PR, Vatanabe IP, Peron R, Grigoli MM, Pedroso RV, Nascimento CMC, et al. Blood-based biomarkers of Alzheimer’s disease: the long and winding road. Curr Pharm Des. 2020;26(12):1300–15.
Article
CAS
PubMed
Google Scholar
Endres K, Deller T. Regulation of alpha-secretase ADAM10 in vitro and in vivo: genetic, epigenetic, and protein-based mechanisms. Front Mol Neurosci. 2017;10:56.
Article
PubMed
PubMed Central
CAS
Google Scholar
de Oliveira TR, Erbereli CR, Manzine PR, Magalhaes TNC, Balthazar MLF, Cominetti MR, et al. Early diagnosis of Alzheimer’s disease in blood using a disposable electrochemical microfluidic platform. ACS Sens. 2020;5(4):1010–9.
Article
PubMed
CAS
Google Scholar
Lundgren JL, Vandermeulen L, Sandebring-Matton A, Ahmed S, Winblad B, Di Luca M, et al. Proximity ligation assay reveals both pre- and postsynaptic localization of the APP-processing enzymes ADAM10 and BACE1 in rat and human adult brain. BMC Neurosci. 2020;21(1):6.
Article
CAS
PubMed
PubMed Central
Google Scholar
Endres K, Fahrenholz F. The role of the anti-amyloidogenic secretase ADAM10 in shedding the APP-like proteins. Curr Alzheimer Res. 2012;9(2):157–64.
Article
CAS
PubMed
Google Scholar
Manzine PR, Barham EJ, Vale Fde A, Selistre-de-Araujo HS, Iost Pavarini SC, Cominetti MR. Correlation between mini-mental state examination and platelet ADAM10 expression in Alzheimer’s disease. J Alzheimers Dis. 2013;36(2):253–60.
Article
CAS
PubMed
Google Scholar
Manzine PR, de Franca Bram JM, Barham EJ, do Vale Fde A, Selistre-de-Araujo HS, Cominetti MR, et al. ADAM10 as a biomarker for Alzheimer’s disease: a study with Brazilian elderly. Dement Geriatr Cogn Disord. 2013;35(1–2):58–66.
Article
CAS
PubMed
Google Scholar
Manzine PR, Ettcheto M, Cano A, Busquets O, Marcello E, Pelucchi S, et al. ADAM10 in Alzheimer’s disease: pharmacological modulation by natural compounds and its role as a peripheral marker. Biomed Pharmacother. 2019;113:108661.
Article
CAS
PubMed
Google Scholar
Colciaghi F, Borroni B, Pastorino L, Marcello E, Zimmermann M, Cattabeni F, et al. [alpha]-Secretase ADAM10 as well as [alpha] APPs is reduced in platelets and CSF of Alzheimer disease patients. Mol Med. 2002;8(2):67–74.
Article
CAS
PubMed
PubMed Central
Google Scholar
Colciaghi F, Marcello E, Borroni B, Zimmermann M, Caltagirone C, Cattabeni F, et al. Platelet APP, ADAM 10 and BACE alterations in the early stages of Alzheimer disease. Neurology. 2004;62(3):498–501.
Article
CAS
PubMed
Google Scholar
Endres K, Fahrenholz F. Regulation of alpha-secretase ADAM10 expression and activity. Exp Brain Res. 2012;217(3–4):343–52.
Article
CAS
PubMed
Google Scholar
Nascimento CMC, Zazzetta MS, Gomes GAO, Orlandi FS, Gramani-Say K, Vasilceac FA, et al. Higher levels of tumor necrosis factor beta are associated with frailty in socially vulnerable community-dwelling older adults. BMC Geriatr. 2018;18(1):268.
Article
CAS
PubMed
PubMed Central
Google Scholar
Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005;112(17):2735–52.
Article
PubMed
Google Scholar
Almeida OP, Almeida SA. Reliability of the Brazilian version of the ++abbreviated form of geriatric depression scale (GDS) short form. Arq Neuropsiquiatr. 1999;57(2B):421–6.
Article
CAS
PubMed
Google Scholar
Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–98.
Article
CAS
PubMed
Google Scholar
Sunderland T, Hill JL, Mellow AM, Lawlor BA, Gundersheimer J, Newhouse PA, et al. Clock drawing in Alzheimer’s disease. A novel measure of dementia severity. J Am Geriatr Soc. 1989;37(8):725–9.
Article
CAS
PubMed
Google Scholar
Brucki SM, Nitrini R, Caramelli P, Bertolucci PH, Okamoto IH. Suggestions for utilization of the mini-mental state examination in Brazil. Arq Neuropsiquiatr. 2003;61(3B):777–81.
Article
PubMed
Google Scholar
Doody RS, Massman P, Dunn JK. A method for estimating progression rates in Alzheimer disease. Arch Neurol. 2001;58(3):449–54.
CAS
PubMed
Google Scholar
Salmon DP, Thal LJ, Butters N, Heindel WC. Longitudinal evaluation of dementia of the Alzheimer type: a comparison of 3 standardized mental status examinations. Neurology. 1990;40(8):1225–30.
Article
CAS
PubMed
Google Scholar
Manzine PR, Barham EJ, Vale FA, Selistre-de-Araujo HS, Pavarini SC, Cominetti MR. Platelet a disintegrin and metallopeptidase 10 expression correlates with clock drawing test scores in Alzheimer’s disease. Int J Geriatr Psychiatry. 2014;29(4):414–20.
Article
PubMed
Google Scholar
Schuck F, Wolf D, Fellgiebel A, Endres K. Increase of alpha-secretase ADAM10 in platelets along cognitively healthy aging. J Alzheimers Dis. 2016;50(3):817–26.
Article
CAS
PubMed
Google Scholar
Tousseyn T, Thathiah A, Jorissen E, Raemaekers T, Konietzko U, Reiss K, et al. ADAM10, the rate-limiting protease of regulated intramembrane proteolysis of Notch and other proteins, is processed by ADAMS-9, ADAMS-15, and the gamma-secretase. J Biol Chem. 2009;284(17):11738–47.
Article
CAS
PubMed
PubMed Central
Google Scholar
Seifert A, Dusterhoft S, Wozniak J, Koo CZ, Tomlinson MG, Nuti E, et al. The metalloproteinase ADAM10 requires its activity to sustain surface expression. Cell Mol Life Sci. 2020. https://doi.org/10.1007/s00018-020-03507-w.
Bleibaum F, Sommer A, Veit M, Rabe B, Andra J, Kunzelmann K, et al. ADAM10 sheddase activation is controlled by cell membrane asymmetry. J Mol Cell Biol. 2019;11(11):979–93.
Article
CAS
PubMed
PubMed Central
Google Scholar
Amour A, Knight CG, Webster A, Slocombe PM, Stephens PE, Knauper V, et al. The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3. FEBS Lett. 2000;473(3):275–9.
Article
CAS
PubMed
Google Scholar
Bertolucci PH, Brucki SM, Campacci SR, Juliano Y. The Mini-Mental State Examination in a general population: impact of educational status. Arq Neuropsiquiatr. 1994;52(1):1–7.
Article
CAS
PubMed
Google Scholar